Diet is a major lifestyle factor in the primary and secondary prevention of numerous chronic diseases, including myocardial infarction, stroke, and diabetes. Epidemiological studies suggest that the beneficial cardiovascular health effects of diets rich in fruits and vegetables are in part mediated by their flavonoid content, with particular benefits provided by one member of this family, the flavanols. This concept is supported by findings from small-scale intervention studies with surrogate endpoints including endothelium-dependent vasodilation, blood pressure, platelet function, and glucose tolerance. Mechanistically, short-term effects on endothelium-dependent vasodilation following the consumption of flavanol-rich foods, as well as purified flavanols, have been linked to an increased nitric oxide bioactivity in healthy humans, and those with increased cardiovascular risk. The critical biological target(s) for flavanols have yet to be identified and the extent to which these acute results are important in the context of long-term human health is unknown. While flavanols represent a promising class of food components with respect to their ability to lower cardiovascular risk the flavanol-rich foods used in many trials have been poorly defined with respect to their flavanol content and flavanol-isomer profile; several studies have lacked appropriate controls, and the long-term randomized controlled intervention trials with flavanol-rich foods are missing. Thus, while the literature regarding flavanols and vascular health is encouraging, more in-depth and well-controlled clinical and experimental studies are needed to better define the potential protective vascular effects of these nutrients and their therapeutic value in cardiovascular medicine.
Introduction
Diet is a lifestyle factor that plays a major role in the primary and secondary prevention of several chronic diseases, including certain cancers, coronary artery disease (CAD), stroke, and diabetes. 1 With respect to vascular disease initiation and progression, current dietary recommendations are aimed at optimizing lipid and lipoprotein profiles, blood pressure, blood glucose levels, and body weight. An additional dietary recommendation is to consume more fruits and vegetables. 2 While there is compelling epidemiological evidence that a diet rich in fruits and vegetables lowers the risk of heart disease and stroke, 3, 4 the mechanisms by which these diets mediate their beneficial health effects are unclear. 5 It is reasonable to suggest that they are multi-factorial in nature. For example, fruits and vegetables are typically low in calories and fat, high in fibre, have a favourable sodium/potassium ratio and contain numerous bioactive plant molecules, including those from a group of phytochemicals called flavonoids ( Figure 1 ). Flavonoids have generated considerable interest as epidemiological studies have suggested an inverse association between the dietary intake of flavonoids and the risk for vascular disease (refs 6-9 and references therein). Flavonoids share a common basic chemical structure. Important subgroups are flavanols, flavonols, flavones, isoflavones, flavanones, and anthocyanins, which are defined by the chemical residues attached to the basic flavonoid structure ( Figure 1A) . A complication of the epidemiological observations regarding members of the flavonoid family is that subtle differences in their chemical structures can translate into marked differences in their absorption and metabolism and bioactivities. 8 While it can be speculated that the putative positive vascular effects of flavonoid-rich diets are due to several of the family members, it is equally reasonable to suggest that the vascular effects are likely to be largely driven by a relatively small number of the family. Conceptually, this is an important point, as the profile of flavonoids in different fruits and vegetables, as well as nuts, varies considerably. 8 If the hypothesis that the reported positive vascular effects of plant food-rich diets are due in part to a limited number flavonoids is correct, this has important implications for dietary recommendations, and potentially for the development of new pharmaceuticals. In this context, flavanols, a subgroup of the flavonoid family ( Figure 1) , are a focus of attention as epidemiological investigations have shown an independent inverse correlation between the dietary intake of flavanol-rich foods and CAD mortality. 10 While the epidemiological findings are provocative, no randomized controlled trials with hard clinical endpoints have been published that corroborate a cause and effect relationship between the intake of flavanols and vascular health. However, several controlled human dietary intervention studies with flavanol-rich foods and beverages have demonstrated positive effects, including the recovery of endothelial function, 11 -15 improvements in insulin sensitivity, decreased blood pressure, 16, 17 and reductions in platelet aggregation. 18 -20 The pharmacological mechanisms of action of flavanols have yet to be identified, but they likely include an enhancement in nitric oxide (NO) bioactivity, modulation of the immune system, and enhanced endothelial homeostatic vascular repair. 21 While it has been speculated that the intrinsic antioxidant capacity of flavanols, and flavonoids in general, underlies their positive vascular effects (refs 22,23 and references therein), this is as unlikely, although select flavonoids may influence the overall level of oxidative stress through secondary mechanisms. 24, 25 Quantitatively, flavanols represent a major group of flavonoids in the western diet. 26 Major sources include chocolate and cocoa (up to 920 -1220 mg/100 g), apples (up to 120 mg/200 g), and tea (up to 300 mg/infusion), however, it must be noted that the profile of flavanols (e.g. (2)-epicatechin, (+)-epicatechin, (2)-catechin, (+)-catechin) in these foods can vary considerably, and it can be changed as a consequence of food processing. 27 Importantly, the methodologies that are typically used to measure flavanols in foods, as well as in biological fluids, do not provide information on the profile of flavanol stereoisomers. The average daily flavanol intake of an adult has been approximated to be in the range of 50 -100 mg. 7 However, there is considerable confusion in the literature, as many authors when reporting dietary intakes do not make a distinction between flavanols per se (which are by definition monomers) and procyanidins, which are oligomers of flavanols. 7 Generally, when viewed as a composite, the flavanol monomers ((2)-and (+)-epicatechin, (2)-and (+)-catechin) are approximately 10% 26, 28 of the combined monomer and oligomer total. We suggest that the pooling of monomers and procyanidins when presenting dietary intake data is inappropriate, given that while monomers and dimers are absorbed in the small intestine, 29, 30 the longer oligomers are not absorbed. Thus, the longer oligomers are unlikely to have direct effects on the vascular endothelium, although we note they may have biological effects within the intestinal track (e.g. they might influence the microbiota, or act as immune modulators). Depending on many factors, peak monomer and dimer plasma concentrations in the nanomolar and low micromolar range are reached at 1 -2 h after the ingestion of a flavanol/ dimer-rich meal. 30 As a result of phases I and II metabolism during absorption and liver passage, the majority of circulating flavanol monomers are methylated, glucuronidated, and/or sulfated metabolites. Importantly, the metabolite profile that occurs in blood is influenced by the profile of the flavanol isomers that is present in the consumed food/beverage ( Figures 1B and 2) . 31 In contrast to the monomers, dimers are not thought to be extensively modified subsequent to their absorption. 32 The biological activities of dimers and the extent to which these activities are influenced by dimer type (e.g. A type vs. B type) are a subject of active research.
Epidemiological evidence
Epidemiological studies suggest that the chronic consumption of a diet rich in plant-based foods is associated with a reduced incidence of CAD, stroke, and myocardial infarction. 3, 4, 33 The positive health effects of fruits and vegetables are often attributed to their macronutrient profile: they are typically low in fat, high in fiber, have low sodium/potassium ratios, and low-energy densities. Fruits and vegetables can also be important sources of a number of healthpromoting micronutrients. These include essential nutrients (e.g. vitamin C, vitamin E, potassium, magnesium), as well as numerous phytochemicals whose bioactivities are poorly defined. Multiple investigators have reported an inverse correlation between the intake of total flavonoids, as well as specific flavonoid classes, and the incidence of cardiovascular mortality. 10 A review of 15 cohort studies examined the relationship between dietary flavonoid intakes and the risk for developing CAD. 10 Thirteen of these prospective studies demonstrated a protective effect of flavanols, procyanidins, flavones, and flavanones in the context of deadly and non-deadly CAD with a reduction of mortality of up to 65%. 
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) and one retrospective anthropological study 39 provide evidence for a primary protective effect of flavanols and procyanidins. In the Zutphen Elderly Study, 806 Dutch elderly men were followed over 15 years. The calculated dietary flavonoid intake was inversely associated with a reduction in ischaemic heart disease mortality with a risk ratio of 0.49 in the highest tertile of daily flavanol intake (average intake 124 + 15 mg/d) as compared with the lowest tertile (average intake of 25 + 40 mg/d). 36 While the above paper is widely, and appropriately, accepted as a landmark study, a limited number of foods were included in the analysis, thus the flavonoid intakes that were reported in this study are lower than what was actually consumed. The prospective Iowa Women's Health Study followed 34 489 postmenopausal women who were free of cardiovascular disease at inclusion. The results published after 13 37 and 16 7 years of follow-up differed slightly in their food classification and analysis, and as a result provide interesting insights into the types of foods that may be driving the epidemiological results. An inverse association between coronary heart disease mortality and catechin and epicatechin intake, as defined by intake of tea, apples and pears, and chocolate, was initially demonstrated. 37 The analysis Flavanols and cardiovascular disease prevention at 16 years of follow-up continued to show reduced cardiovascular risk with increased intakes of foods the authors defined as procyanidin-rich (as noted above procyanidins are oligomers of flavanols; foods in this category included chocolate, apples and seeded grapes), however, as a separate class, the dietary intake of flavanols was not associated with a reduced risk. The flavanol-rich foods in their analysis were identified as apples, red wine, and green tea. 7 The seeming discrepancy of the findings between Arts et al. 37 and
Mink et al. 7 with respect to flavanols per se is likely due in part to differences in how the data from chocolate and seeded grapes were treated. In the paper by Mink et al. 7 the flavanol intake data from these foods were pooled with the procyanidin intake data from these foods. Importantly, the analysis of the 16 years data continued to show an inverse association between cardiovascular mortality and high chocolate and fruit intake. Recently, Buijsse et al.
extended these findings to middle-aged Germans of both sexes in the Potsdam Arm of the European Prospective Investigation into Cancer and Nutrition. The authors reported an inverse relationship between chocolate consumption and cardiovascular disease risk (myocardial infarction, stroke, 8 years follow-up) in a large cohort (n ¼ 19 357) of middle-aged German participants of both sexes, without cardiovascular disease at inclusion. They observed that in the quartile characterized by the lowest chocolate consumption (1.7 g/day) 106 myocardial infarctions and strokes occurred, whereas 61 events occurred (combined relative risk of 0.61) in the quartile with the highest chocolate consumption (7.5 g/day). In the latter group, both systolic and diastolic blood pressures were significantly lower (1 mmHg) than the referent low-chocolate consumption quartile. Baseline blood pressure explained 10 -12% of the risk reduction. Counter intuitive to the idea that a high vegetable intake is beneficial, the subgroup with the lowest risk was the group with the lowest vegetable intake while also having the highest chocolate intake. A limitation of this study is that chocolate consumption was only estimated as one item on the food-frequency questionnaire, making a more qualified evaluation of the associated intake of potential bioactive compounds, including flavanols, impossible. In addition, the flavanol/procyanidin content of cocoa/chocolate (as well as other flavanol/procyanidin-rich foods) products can be markedly influenced by food processing, as well as agricultural practices. 40 This is an important issue that must be considered when evaluating data from epidemiological studies. Evidence in support of the concept that a high intake of dietary flavanols and procyanidins is associated with positive vascular health effects is provided by studies investigating the mortality resulting from cardiovascular events in the Kuna Indians, who live on the San Blas Islands off the coast of Panama. Traditionally, the Kuna, who reside on the islands, consume large volumes of cocoa on a daily basis, and as a group they are characterized by a low incidence of age-related hypertension. When Kuna migrate from the islands to the mainland, they tend to decrease their cocoa intake, and adopt a more westernized diet that is relatively low in flavonoids. Following their movement to the mainland, they typically develop age-related hypertension. 39 That the high cocoa consumption of the Kuna living on the islands can be linked to their reduced risk for hypertension is supported by the observation that urinary nitrite and nitrate excretion, potential NO markers, are higher in Kuna living on the islands than for those living on the mainland. 13 It has been reported that cardiovascular mortality of the Kuna is considerably lower than that of other Pan-American populations (9 vs. 83 age-adjusted deaths/100 000). The determinants of this effect seem to be predominantly environmental rather than genetic, given that this protection is lost on migration of Kuna Indians to Panama City. 39 Recently, a prospective study (Stockholm Heart Epidemiology Program
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) was published that reported a secondary preventive effect of chocolate intake in a group of 1169 non-diabetic patients after first acute myocardial infarction with a mean follow-up of 8 years. In this study, a high chocolate intake was associated with a reduction in cardiac mortality in patients that consumed 50 g of chocolate twice or more per week, with a hazard ratio of 0.34. While the above epidemiological studies are promising, epidemiological studies inherently deliver associations. Thus, they are limited with respect to proving cause and effect relationships, or in giving mechanistic insights as the observed associations may be due to strong confounders. An important potential confounder in this context is reporting bias. Subjects with an unhealthy lifestyle may report lower chocolate intake as they may feel guilty about it. In several cases, nutrition intervention studies based on hypotheses generated from epidemiological studies have been disappointing, as exemplified by the report that vitamin E and C supplementation did not reduce major cardiovascular events the Physicians' Health Study II. 42 
Clinical intervention studies
While the data from epidemiological studies can be directional, randomized controlled clinical intervention studies are the preferred method for generating the evidence that is needed to causally link increased dietary flavanol consumption with effective cardiovascular disease prevention. Key questions that should be considered when conducting such trials include, what are the meaningful endpoints that need to be studied and what populations should be used? Ideally, flavanol-rich foods should be given to large groups of subjects in a randomized placebo-controlled study. Study populations should include subjects with (secondary prevention) or without (primary prevention) cardiovascular disease, and clinical hard endpoints including death, myocardial infarction, stroke, but also hospitalization or clinical symptoms, should be studied over a long-time frame. The study populations should be large enough to address age and sex considerations and to ensure that the results are applicable to the public. To our knowledge, no such trials have been conducted with any member of the flavonoid family. However, several small-scale and short-term clinical studies have been performed with cardiovascular surrogate endpoints thought to reflect key pathophysiologically relevant entities. These studies are useful as they can help to elucidate the mechanisms by which flavanols mediate their pleiotropic effects, as these surrogate parameters reflect key pathophysiological entities implied in cardiovascular disease development and progression. These endpoints include, but are limited to, endothelial vasomotor function, blood pressure, blood lipids, glucose tolerance, and activity of platelets, inflammatory and circulating progenitor cells.
Independent of the endpoint studied, certain limitations apply to many of the flavonoid feeding studies that have been conducted to date. For example, many of the papers in this area describe studies that lack proper food/beverage controls; they often provide minimal compositional analysis of the foods that are being tested; the studies are often of limited duration; and in many cases there is a lack of relevant study populations. Ideally, the control food/beverage should be indistinguishable from the intervention by means of taste and appearance to assure proper blinding and exclude bias. The controls should be matched for micro-and macronutrient composition, including other potential bioactive compounds, such as theobromine and caffeine in the case of cocoa or chocolate. Illustrative of the above, in several studies where the putative positive health effects of a flavonoid-rich chocolate was being studied, a white or milk chocolate was used as a control for a 'high flavanol' dark chocolate. The use of this type of 'control' clearly prohibits blinding, and these food products, in addition to having differences in their flavonoid content, vary in their content of numerous other nutrients and bioactive compounds such as methylxanthines. Similar to the above example, in many tea studies, water has been used as a 'control'. The lack of appropriate food/beverage controls in studies evaluating the putative vascular effects of specific flavonoids is a significant issue that needs to be addressed in a systematic manner. Until this is done, progress in the field will be hampered. Another difficulty with the interpretation of the collection of studies done to date is that when evaluating the information on the flavanol content of the test foods used, it is evident that the amounts vary considerably across studies, a fact that complicates the comparison of the results from the investigations. Another impediment to a comprehensive interpretation of the studies reported to date is that in several cases, plasma concentrations of flavanols and flavanol metabolites are not reported. In the cases where values are reported, there is minimal standardization as to when the blood samples were collected. This is an issue in the case of flavanols, as the metabolic turnover of these nutrients is very fast with a halflife of approximately 1-2 h. We suggest that one reason the importance of dietary flavanols with respect to vascular health has received minimal attention is the common use of fasted samples in clinical settings, as well as in many epidemiological studies. With the caveats noted above, below we review some of surrogate endpoints that have been studied in short-term flavanol studies. We primarily cite literature from the cocoa/chocolate field, as the test foods used in many of these studies have been better characterized than what is typically reported in studies with tea or grape products.
Endothelial function
The endothelium maintains vascular homeostasis through multiple complex interactions with cells in the vessel wall and lumen. It regulates vascular tone by balancing the production of vasodilators, most importantly NO, prostaglandins, and endothelium-derived hyperpolarizing factor, and vasoconstrictors including endothelin-1 ( Figure 3) . The severity of endothelial dysfunction relates to a patient's risk for experiencing an initial or recurrent cardiovascular event. 43 A number of interventions known to decrease cardiovascular risk, including diets rich in plant foods, exercise, smoking cessation, weight reduction, medication with angiotensin-converting enzyme (ACE) inhibitors, and statin administration are thought to mediate their vascular protective effect in part by restoring endothelial function. 43, 44 Several clinical intervention studies have tested the effect of flavanol-rich foods including cocoa, dark chocolate, tea, grape juice, and red wine on endothelial vasodilator response. 14 In several studies, endothelium-dependent vasodilation was measured as flow-mediated vasodilation of the brachial artery (FMD) using high-resolution ultrasound in a few studies with peripheral artery tonometry (PAT) of the finger tips, and in one study using the cold pressor test during coronary angiography. 45 In general, these studies show that high-flavanol/procyanidin interventions induce an acute and sustained increase or restoration of endothelium-dependent vasodilation in healthy subjects, 46 - shown to be significant statistical predictors of the FMD increase. Longer term studies with multiple daily dosing regimens for up to 6 weeks have shown that there can be a sustained increase in FMD and PAT, which can be increased by additional application (acute or chronic). 11, 56, 59 A causal relationship between the intake of flavanols and an improvement of vascular function has been further substantiated in studies where pure flavanols, (2)-epicatechin and epigallocatechin-gallate provided orally, were shown to have acute FMD-enhancing effects. 13, 62 In parallel with the FMD and PAT effects, an increase in circulating plasma NO storage forms, RXNO (S-and N-nitros(yl)ated NO species (RX designates that NO is bound to different residues 'R' via different bonds 'X') and nitrite, has been observed in several of these dietary intervention trials including one applying pure (2)-epicatechin. 11, 13, 63, 64 Importantly, these NO species represent both, a marker for endothelial NO synthesis and bioactive NO storage pools, which have intrinsic vasodilator activity. 65, 66 The increase in both the FMD and NO species can be abolished by systemic inhibition of NOS using L-NMMA, 12, 13 and the PAT response can be blocked by L-NAME. 46 In the context of flavanol-associated cardiovascular effects and their potential mechanisms, these data support the concept that the acute and short-term intake of flavanols can be causally linked to an increase in endothelium-dependent vasodilation in humans. Still, the molecular target(s) of the flavanols have yet to be identified, there is limited information regarding the amount of flavanols that are needed on a chronic basis to elicit the above endothelial effects, and most importantly, it still needs to be shown that intake of flavanols on a chronic basis can prevent the development and progression of vascular disease.
Blood pressure, lipids, glucose tolerance, and inflammation
Aside from flavanol-associated effects on conduit artery vasodilation, several studies have shown that there can be effects on blood pressure. Studies by Taubert, 16,67 Grassi, 52, 53 and others 17 suggest that in healthy subjects, patients with untreated essential hypertension, and pre-hypertension, blood pressure can be reduced following the consumption of dark chocolate compared with white chocolate. In the study by Taubert et al., 16 participants with untreated essential hypertension received 6.3 g of dark chocolate per day over 18 weeks, and a significant drop in systolic and diastolic blood pressure was observed. While the results that are reported are provocative, a limitation of this study is that white chocolate was used as a control food product, thus the study was not blinded Furthermore, the different compositions of white and dark chocolate make it difficult to identify specific bioactives, such as flavanols, in the context of blood pressure lowering. We suggest that at present we do not have conclusive data from sufficiently controlled interventional trials to support the notion that flavanols possess antihypertensive properties. Similar limitations apply to several studies that have reported that the consumption of flavanol-rich foods can result in reductions in LDL cholesterol, and improvements in glucose tolerance. 52, 53, 68 While these observations are provocative, they need to be confirmed in well-controlled studies. Multiple studies suggest that the acute consumption of flavanol-rich foods/beverages can also result in an inhibition of platelet activity and aggregation, 18, 20, 69, 70 and inhibit monocyte and neutrophil activation in vitro and ex vivo. 71 It has also been reported that the chronic consumption of a high flavanol diet can result in a reduction in select pro-inflammatory markers. 72 While space constraints do not allow for an in-depth review of this literature, these observations support the concept that dietary flavanols have positive vascular effects through a multiplicity of mechanisms. We note that the seemingly diverse actions of flavanols are likely interrelated. Illustrative of this are the observations that an increase in NO can result in a reduction in platelet activation, 18, 19, 71 as can improvements in glucose tolerance.
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Regenerative processes: impact on circulating angiogenic cells
Bone marrow-derived circulating angiogenic cells (CACs; also referred to as early endothelial progenitor cells 74 ) may contribute to the recovery and maintenance of endothelial function. 75 Primary and secondary preventive lifestyle interventions and statin therapy can enhance endogenous endothelial repair mechanisms by stimulating CAC mobilization. 76 It has been reported that 2-4 weeks of flavanol-rich foods can mobilize EPCs in CAD patients, healthy smokers and non-smokers. 64, 77, 78 In a randomized double-blind study in patients with coronary artery disease a cocoa -flavanol intervention (30 days)-related increase in FMD and decrease in blood pressure was paralleled by a significant increase in CD34/ KDR and CD133/KDR-CACs. 64 Similarly, in healthy smokers, green tea (8 g/day) ingestion (one armed study) over 2 weeks led to a significant increase in FMD and EPCs. Interestingly, a smaller amount of this green tea (5 g/day) over 4 weeks failed to increase EPCs in haemodialysis patients despite significantly increased FMD. 55 Huang et al. 77 showed that 3 weeks of 300 ml red wine consumption in healthy subjects led to a significantly higher number of EPCs that was paralleled by increased FMD response, NOX levels, and decreased asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of NOS, however, other alcohol-containing drinks (beer and vodka) were used as controls, prohibiting proper blinding. Red wine (100 ml/day), beers 250 ml/day), vodka (80 ml/day), water (100 ml/day) Potential mechanisms contributing to flavanol-induced changes in endothelial vascular health: experimental evidence
The mechanisms by which flavanols mediate their vascular effects are not fully understood. As supported by clinical data, animal, and in vitro studies, short-term effects may be related to an increase in NOS activity. 24 The precise mechanism and biological target structure(s) or receptor(s) have not been identified in vivo.
Besides direct effects on eNOS, inhibitory effects on pathways that may negatively affect NOS activity including NADPH oxidase, ACE, ADMA, and endothelin-1 have been proposed to be affected by flavanols. 24 The oral administration of flavanol-rich food extracts (red wine polyphenol extract over 7-10 days) or the flavanol monomer catechin to rats led to increased acetylcholine NOS-dependent vasodilation, NO production, and decreased superoxide (O 2
2.
) production of aortic rings isolated from these animals along with a significant decrease in blood pressure. 79, 80 These results were corroborated by Ramirez-Sanchez et al. 81 showing that nano-micromolar concentrations of (2) formation. However, this mechanism has yet to be demonstrated in vivo. Endothelins (ETs), a family of vasoactive peptides, are rapidly produced by endothelial cells in response to tissue injury and play a major role in vascular dysfunction and vascular disease. 83 Whereas (2-)-epicatechin did not inhibit ET-1 synthesis in vitro, oral application of epicatechin lowered ET-1 levels along with increasing NO species in healthy human subjects. 63, 84 Together with the results from studies showing that aortic rings do not dilate in the presence of flavanol monomers, 85 the partly discrepant results from in vitro and in vivo systems imply that flavanol metabolites, rather than the parent molecule, trigger many of the critical biological activities that are pertinent with respect to vascular health. In the context of long-term effects, general patterns of cellular adaptive or regenerative responses have to be considered on the overall tissue/organ level as well as on an individual cell level with the eNOS axis likely being only one of the pathways involved. Based on the results from murine models, it has been suggested that the regular ingestion of flavanols and flavanol extracts can inhibit aortic plaque size by up to 40%, 86 inhibit the expression of inflammatory cytokines, and reduce I/R injury with a 30% reduction in infarct size. 87 While the above mechanistic work is of interest, several limitations have to be kept in mind when evaluating experimental studies aiming at understanding the mechanisms by which flavanols mediate their vascular effects. With respect to in vitro models, including cell culture systems and isolated vessel systems such as aortic rings, limitations include the relevance of flavanol compounds that are used (e.g. parent compounds vs. metabolites), and the concentrations of the flavanol/flavanol metabolite used in the experimental system. Regarding the relevance of flavanol compounds used in experimental set-ups, flavanol absorption and metabolism need to be considered and accounted for. As noted above, the majority of 'flavanols' present in most foods, such as cocoa are present as oligomers (procyanidins), rather than monomers, and it is now well established that to a great extent only the monomers and dimers are absorbed. Thus, one needs to carefully evaluate the data obtained from in vitro studies when longer oligomers, and whole food extracts, are added to the media, 85, 88 particularly in the context of cardiovascular research. Furthermore, monomers, which are absorbed, are rapidly metabolized. Thus, in plasma, following absorption, the parent molecule (2)-epicatechin ( 5-250 nM) represents a minor portion of total plasma flavanols (,3 uM), yet, the biological effects of the major classes of epicatechin metabolites, including methylated, glucuronidated, and sulfated adducts have received only limited study to date. 89 As noted above, 3 ′ -O methyl epicatechin can be an inhibitor of NADPH oxidase and may thereby enhance NO bioactivity in vitro (ref. 24 and references herein). Schewe et al.
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hypothesized that flavanol glucuronides serve as water soluble transport forms of flavanols in blood that can be cleaved by endothelial b-glucuronidase and then stored as agycones. A second major limitation of many experimental studies is the high concentration of flavanols used in them. Plasma concentrations of physiological flavanol metabolites are in the nanomolar and low-micromolar range, whereas many in vitro studies have been performed in the micromolar range. In this context another layer of complexity has to be taken into account. Aglycone epicatechin, due to its high protein binding, is rapidly taken up by cells. 90 A third major limitation of experimental work relates to the question as to whether the experimental system is relevant for human physiology or disease. Results obtained on the cellular level need to be considered in concert with meaningful in vivo read-outs of a physiological response in appropriate animal models, and linked back to clinically relevant human models.
Conclusions
While flavanols represent a promising class of food components that are associated with lower cardiovascular risk and can positively affect cardiovascular surrogate parameters in the short term, epidemiological studies are prone to confounders and no long-term randomized controlled dietary intervention trials with hard clinical endpoints are available to date. More clinical and experimental studies are needed before flavanols can be considered as a feasible therapeutic option in cardiovascular medicine. Conflict of interest: none declared.
